Table 3.
WPAI:SHP v2.0 scores for overall work impairment
| WPAI:SHP v2.0 score, mean (SD), % | Vehicle (n = 244) | 0.75% Ruxolitinib cream (n = 483) | 1.5% Ruxolitinib cream (n = 481) | |||
|---|---|---|---|---|---|---|
| n | Score | n | Score | n | Score | |
| Absenteeism | ||||||
| Baseline | 136 | 5.2 (15.4) | 269 | 7.9 (20.5) | 273 | 3.9 (13.4) |
| Week 2 | 109 | 9.0 (21.3) | 224 | 6.0 (17.6) | 232 | 4.5 (14.8) |
| Week 4 | 96 | 13.2 (25.9) | 219 | 7.7 (19.8) | 239 | 6.9 (18.5) |
| Week 8 | 99 | 12.7 (21.3) | 218 | 7.7 (21.5) | 229 | 7.5 (19.1) |
| Presenteeism | ||||||
| Baseline | 135 | 33.9 (27.4) | 267 | 30.1 (25.6) | 272 | 29.8 (24.1) |
| Week 2 | 107 | 28.0 (25.7) | 221 | 14.6 (18.6) | 231 | 14.7 (19.9) |
| Week 4 | 92 | 23.2 (26.0) | 215 | 11.9 (17.0) | 236 | 10.1 (17.1) |
| Week 8 | 99 | 22.0 (24.3) | 213 | 10.1 (17.3) | 227 | 9.5 (17.1) |
| Overall work impairment | ||||||
| Baseline | 135 | 36.4 (28.3) | 267 | 33.6 (27.9) | 272 | 31.8 (25.4) |
| Week 2 | 107 | 32.4 (27.8) | 221 | 18.0 (22.4) | 231 | 17.8 (22.9) |
| Week 4 | 92 | 29.4 (29.2) | 215 | 16.8 (21.6) | 236 | 14.7 (22.0) |
| Week 6a | NA | 30.2 (NA) | NA | 15.6 (NA) | NA | 15.1 (NA) |
| Week 8 | 99 | 31.0 (27.9) | 213 | 14.3 (22.3) | 227 | 15.5 (22.8) |
| Daily activity impairment | ||||||
| Baseline | 243 | 33.2 (27.6) | 483 | 31.3 (27.2) | 479 | 32.2 (26.9) |
| Week 2 | 223 | 27.5 (26.5) | 457 | 16.5 (21.5) | 455 | 13.3 (18.1) |
| Week 4 | 205 | 23.8 (24.6) | 452 | 12.3 (18.3) | 456 | 10.8 (17.8) |
| Week 8 | 201 | 22.3 (25.3) | 427 | 10.5 (17.6) | 444 | 10.5 (17.5) |
NA not available, SD standard deviation, WPAI:SHP v.2.0 Work Productivity and Activity Impairment Questionnaire-Specific Health Problem version 2.0
aWeek 6 overall work impairment data points were imputed by taking the mean of week 4 and week 8; these data were used in the economic model